Background The majority of patients undergoing surgical treatment for ST-elevation
myocardial infarction receive antifibrinolytic therapy to limit blood loss. This approach …

Background Antifibrinolytic agents are commonly used during cardiac surgery to minimize
bleeding and to reduce exposure to blood products. We sought to determine whether …

BACKGROUND: Aprotinin is superior to other antifibrinolytic drugs for preventing major
blood loss after cardiac surgery but may also increase perioperative mortality. It remains …

Background Aprotinin has recently been associated with adverse outcomes in patients
undergoing cardiac surgery. We reviewed our experience with this agent in patients …

ContextAcute safety concerns have been raised recently regarding certain hemorrhage-
sparing medications commonly used in cardiac surgery. However, no comprehensive data …

Background Aprotinin (Trasylol) is used to mitigate bleeding during coronary-artery bypass
grafting (CABG). Accumulating evidence suggests that this practice increases mortality …

BACKGROUND: Our aim was to investigate postoperative complications and mortality after
administration of aprotinin compared to tranexamic acid in an unselected, consecutive …

Background: Because of recent concerns about the safety of aprotinin, we updated our 2007
Cochrane review that compared the relative benefits and risks of aprotinin and the lysine …

Background Aprotinin is a serine protease inhibitor used to limit perioperative bleeding and
reduce the need for donated blood transfusions during cardiac surgery. Randomized …

Cardiopulmonary bypass (CPB) is associated with defective haemostasis which results in
bleeding and the requirement for allogenic blood product transfusions in many patients …